http://www.carnabio.com/english/press_release/ Press Release http://www.carnabio.com/english/press_release/press2008.html#pr24 Kobe, Japan, August 6, 2008 Carna Biosciences, Inc.(“Carna”) is pleased to announce the signing of a collaborative agreement with caliper Life Sciences, Inc. USA (“Caliper”). Carna will supply a set of discrete protein kinases aiding the expansion of Caliper’s kinase profiling and assay development services, and ProfilerPro Kinase Selectivity Assay Kits. Caliper’s products and services are widely used and highly regarded by leading pharmaceutical and biotech companies. The selection of Carna as a Preferred Provider enhances the visibility and use of Carna’s products in the area of kinase inhibitor drug discovery – a major focus of targeted therapy in the areas of cancer, neurological, and autoimmune diseases. 2008-08-07T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2008.html#pr22 Carna Biosciences has decided to establish wholly-owned subsidiary, CarnaBio USA, Inc., located in Massachusette, USA. This is to meet an increasing demand of customers of North America that we will be able to provide our kinase related products and services in a timely manner. Operation is scheduled to start in June, 2008. 2008-04-18T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2007.html#pr19 Carna Biosciences and OSI Pharmaceuticals, Inc. have signed collaboration and service agreement to jointly provide kinase focused leads discovery services to clients. 2007-10-11T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2007.html#pr20 Carna Biosciences, SBI Biotech Co., Ltd. and CrystalGenomics, Inc. have signed collaborative research and development agreement to further develop drug candidate compounds. 2007-04-06T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2006.html#pr17 Carna Biosciences and Enamine, Ltd. have accounced the signing of a collaboration agreement to cooperate on discovery and development of lead compounds against targeted kinase. 2006-05-17T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2006.html#pr16 Carna Biosciences and ChemDiv, Inc. have announced the signing of a collaboration agreement to form a partnership to develop and market annotated kinase focused libraries targeting kinases for various pathways and disease areas of which have been difficult for industry to produce drug candidates to date. 2006-03-30T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2006.html#pr15 Carna Biosciences, Ginkgo Biomedical Research Institute Co., Ltd. (presently SBI Biotech Co., Ltd.) and CrystalGenomics, Inc. have agreed on collaboration research on the discovery of drug candidate compounds against targetted kinase of Cdc7-ASK. Cdc7-ASK is reported to be important target as anticancer drug. The companies aim to obtain hit compounds within 1 year and complete optimization process to obtain novel candidate compound within 2 years. The candidate compound obtained from the collaboraion research will be jointly owned by 3 companies. 2006-03-14T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2006.html#pr14 In March 2006, Carna Biosciences has successfully closed series E equity finance, which increased the company's capital to 1,521.7 million yen. 2006-03-07T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2006.html#pr13 Carna Biosciences, Oncotherapy Science, Inc. and CrystalGenomics, Inc. formed collaborative relationship to discover novel hits against the targeted 2 types of protein kinases, identified by Oncotherapy Sciences, Inc. which are effective and highly selective for cancer. Carna Biosiences is responsible for kinase production, assay development and screening while CrystalGenomics, Inc. is responsible for virtual screening, kinase library development and crystallography. The candidate compounds obtained from the collaborative research will be jointly owned by 3 companies. 2006-02-01T00:00:00+09:00 http://www.carnabio.com/english/press_release/press2005.html#pr11 Carna Biosciences and CrystalGenomics, Inc. jointly announce the signing of a service agreement with Rigel Pharmaceuticals, Inc. in the field of structure based drug design. 2005-06-20T00:00:00+09:00